Kangtai Biological Products
300601.SZShenzhen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile300601.SZ · Stock Price
CNY 14.12+0.31 (+2.24%)
Market Cap: $2.3B
Historical price data
Overview
A leading Chinese vaccine developer and manufacturer with a broad infectious disease portfolio and significant international expansion.
Infectious Disease
Technology Platform
A comprehensive vaccine platform encompassing live attenuated, inactivated, recombinant protein, polysaccharide conjugate, combination, viral vector, and mRNA technologies, with a focus on multivalent and novel carrier systems.
Opportunities
Significant growth opportunities exist in the international expansion of its marketed portfolio, particularly in emerging markets, and the future commercialization of its high-value late-stage pipeline candidates like the 20-valent pneumococcal and pentavalent rotavirus vaccines.
Risk Factors
Key risks include intense competition from global vaccine giants (Pfizer, GSK, Merck) and other Chinese players, pricing pressures in both domestic and international tenders, and execution risks associated with complex global regulatory filings and supply chain management.
Competitive Landscape
BioKangtai competes with multinationals (Pfizer's Prevnar 13/20, GSK) and domestic Chinese vaccine firms (Walvax, Sinovac, CNBG). Its differentiation lies in its broad, integrated platform, specific conjugate vaccine technologies (e.g., dual-carrier), and a strategic focus on technology transfer and partnerships in emerging markets.